

Article

Not peer-reviewed version

Targeting the TLK1-Nek1-Mediated Activation of YAP1 Attenuates PD-L1 and Atinflammation Set for Prostate Cancer Immuno-evasion

[Damilola Olatunde](#) , [Xiuping Yu](#) , [Omar Coronel Franco](#) , [Arrigo De Benedetti](#) *

Posted Date: 17 July 2025

doi: 10.20944/preprints202505.1821.v2

Keywords: advanced CRPC therapy; CRPC; ICB; PD-L1; TLK1; NEK1; YAP



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Article

Targeting the TLK1-Nek1-Mediated Activation of YAP1 Attenuates PD-L1 and Antiinflammation Set for Prostate Cancer Immuno-evasion

Damilola Olatunde, Xiuping Yu, Omar Coronel Franco and Arrigo De Benedetti *

Department of Biochemistry and Molecular Biology, Louisiana State University Health Shreveport, Shreveport, LA 71103

* Correspondence: Arrigo.debenedetti@lsuhs.edu

Abstract

Our recent studies on the activation of the TLK1B>NEK1>YAP1 axis following ADT/ARSI have revealed the outlines of an innate immunity integration response that includes PD-L1 expression and alterations in cGAS-pSTING and pSTAT1/3, which drive the immuno-evasion of PCa cells after prolonged treatment with ARSI and can thus contribute to CRPC progression. These observations are consistent with the general assessment that human PCa is immunologically ‘cold’ and unresponsive in the long term to ICB treatments aimed at combating mCRPC once it is established. Here, we utilized a TLK1 inhibitor (J54) and a PD-L1 monoclonal antibody to suppress tumor growth in a syngeneic PCa model (TC2 in C57/Bl6 mice), in addition to Enzalutamide (ENZ). Remarkably, the combinations of ENZ+J54 or Atez+J54 resulted in durable suppression of tumor growth, partly explained by a strong antitumor immune response. These observations were further generalized using a genetic model (TRAMPxNEK1+/- mice), in which we occasionally observed progression to genuine PRAD with age. In cases when it did progress, there was clear evidence of a strong immunoreactive response, spatially discernible with VISIUM (10XG) of PEFF prostate sections.

Keywords: advanced CRPC therapy; CRPC; ICB; PD-L1; TLK1; NEK1; YAP

Introduction

The standard of care for advanced Prostate Cancer (PCa) consists of Androgen Deprivation Therapy (ADT) and the use of ever more effective therapies targeting the Androgen Receptor (AR) under different mechanisms (rev in [1]). Unfortunately, these treatments ultimately fail due to various PCa adaptation pathways [2] resulting in the incurable phase of the disease: metastatic castration resistant prostate cancer (mCRPC). These pathways often participate in normal cellular processes but become oncogenic after ADT [3]. One of the most common mechanisms is the ability to integrate AR signals with ever-diminishing residual testosterone, with the frequent participation of Yes-associated protein (YAP) as AR co-activator (rev in [4]).

We previously uncovered the upregulation of Tosl-like kinase 1B (TLK1B) through mTOR-dependent translational derepression after ADT, which is critical for promoting the flux through TLK1>Nek1-T141>ATR>Chk1 axis in mediating the DNA damage response (DDR) and cell cycle checkpoint while transiting from Androgen Sensitive (AS) to Insensitive (AI) growth for LNCaP, VCaP, TRAMP-C2 cells, and in preliminary experiments in a AR+/PDX model [5,6]. In addition, we found that overexpression of wt-Nek1 (but not the T141A kinase-hypoactive mutant that TLK1 cannot phosphorylate) hastens the progression of LNCaP cells to AI growth. The protective TLK1>Nek1 DDR-induced cell cycle arrest does not explain the rapid growth recovery observed in ARSI-treated cells when Nek1 is overexpressed[7,8] and suggests that Nek1 may have additional functions. We have ample evidence that it regulates the Hippo pathway because we found that Nek1 interacts with and activates YAP through Y407 phosphorylation [6,9]. It was reported that ectopic

expression of YAP is sufficient to convert LNCaP cells from AS to AI growth[10]. It was also determined that the ETS-related gene (ERG) (and the common *TMPRSS2-ERG* rearrangement) activates the transcriptional program regulated by YAP and that prostate-specific activation of either ERG or YAP in mice induces similar transcriptional changes and results in age-related prostate tumors[11]. This work provided direct genetic evidence of a causal role for ERG in prostate cancer and revealed a connection between ERG and the Hippo pathway. However, in human PCa, the key components/regulators of the Hippo pathway are still unknown. Recently, we found that SCID xenografts of the VCaP model that carry such common translocation initially respond well (with shrinkage of the tumors) to the combination of Enzalutamide (ENZ) and J54 (TLKi). Still, ultimately, in about 50% of the mice, the tumors will re-grow. This is despite the fact that J54[12] is still capable of suppressing pNek1-T141 and its target, pYAP-Y407[13,14], the active/nuclear form of the co-activator. We favored the hypothesis that the *TMPRSS2-ERG* oncogenic translocation can implement a parallel AI (CRPC) conversion than the one mediated by the AR/YAP integration, with elevated expression of their target genes, including epithelial to mesenchymal transition (EMT) and androgen independence determinants[13].


Evidence is accumulating that YAP contributes to cancer immunosuppression[15,16]. An important distinction that characterizes YAP's co-opted regulation of cancer progression genes is its capacity to mediate YAP-induced programmed death ligand 1 (PD-L1) expression, which drives immune evasion [17–19]. PD-L1, a type I transmembrane surface glycoprotein encoded by the CD274 gene, promotes T-cell tolerance and inhibits its effector functions[20]. Its expression correlates with dysregulation of the immune response that characterizes tumor progression and therapy resistance [21]. Immune checkpoint inhibitors (ICIs) are primarily used for tumors. However, their efficacy is significantly reduced due to therapy resistance[22]. The link between treatment-induced YAP-Y407 phosphorylation-mediated influence on immune cell recruitment to the tumor site remains unexplored. Our findings show that pIRF3 in recidive VCaP xenografts was suppressed with J54, thus curtailing a key branch of innate immunity through the expression of INF- γ , which is also critical for PDL-1/2 expression and avoiding immune surveillance[23]. At the same time, pSTAT1 was dramatically increased, likely through activation of cGAS/STING from the release of nuclear and mitochondrial DNA upon implementation of apoptosis [6,24–26]. Conversely, pSTAT3 was elevated in tumors of mice treated with ENZ but not concomitantly with J54 – all this suggesting prolonged treatment with ARSI suppresses anti-tumor-induced, YAP- and NFkB-modulated inflammatory responses[27]. In fact, our single-cell VISIUM analysis of advanced age TRAMP PCas revealed that in TRAMP mice crossed to be haploinsufficient for Nek1, there was a considerable infiltration of CTLs after castration of the animals, which was found to elevate expression of TLK1B. Hence, we hypothesize that the addition of ICB modulators could still work well for PCa patients who may not be responding optimally to our ENZ+J54 treatment, as we anticipate it may happen for cases harboring *TMPRSS2-ERG* translocation (reported to be as many as 45% of patients). We thus initiated xenograft studies in syngeneic/immunocompetent mice to investigate this proposition using the TRAMP-C2 cells model in C57Bl/6 mice[28], which is already relatively well characterized for its immune-inducing responses. Our findings suggest a change of an overall immunologically 'cold' tumor, the typical condition of most PCa [29,30], into a 'hot' one with the combination of ICIs and TLK1 axis inhibition.

Results

TLK1i and ICI Combination Reversed Aggressive PCa Tumor Growth Phenotypes with Improved Immune Signaling in Mice

To evaluate the treatment efficacy of ADT, ICIs, and TLK1i alone or in combination, we introduced TRAMP-C2 cell lines subcutaneously into C57BL/6 immunocompetent mice and administered treatment biweekly. Tumor growth measurements taken during the four weeks of treatment revealed a significant reduction in tumor volume for the ENZ+J54 and J54+Atez groups,

compared to the progressive increase in tumor volume of the control, ENZ, and J54 groups (Figure 1A). Atez alone, ENZ+Atez, and the ENZ+Atez+J54 treatments exhibited no significant changes. Consistent with tumor volume, immunoblot of the excised tumor from the respective groups showed a significantly reduced expression of PD-L1 (Figure 1B) for the ENZ+J54 and J54+Atez groups in contrast to the elevated PD-L1 expression found in the control and other treatment groups (a slower mobility band may be a PD-L1 ubiquitinated product possibly by SPOP [31], which is one of most mutated genes in human PCa; similarly smaller immunoreactive bands could be proteasome products). ENZ alone (reported to lag C2 tumors growth by ~10 days if injected at 20mg/kg [32]) did not appear to have an impact at the effective dose we tested. Rather we observed the rapid development of resistance to ENZ (CRPC phase due to the previously noted overexpression of PD-L1 after ENZ treatment). The combination of ENZ+J54 (suppressing PD-L1) resulted in the best tumor regression, whereas ATEZ alone or with ENZ had primarily cytostatic effects. The triple combination was no more effective than ENZ + J54, as expected, targeting the same PD-L1 suppression effect. To determine the immunomodulatory effects characterizing the tumor volume and PD-L1 expression dynamics in mice, we performed immunoblot analyses for innate immune mediators in tumors derived from the respective treatment groups. Increased PD-L1 in ENZ-treated groups was associated with elevated levels of TLK1B, pNek1-T141, pYAP1-Y407 with Atez alone, J54 alone and Enz+Atez showing similar expression patterns for these mediators (Figure 1C). In contrast, J54 In combination with Enz/Atez significantly reduced TLK1B, pNek1-T141, pYAP1-Y407 protein expression while J54 + Atez + Enz treatment exhibited mixed effects, potentially due to complex drug interaction that diminish their net positive effect. Notably, similar expression of pSTING was biased towards pSTAT3 expression in control, Enz alone, Atez alone, J54 alone and Enz+Atez treatment groups but not in the J54 + Enz/Atez groups where pSTAT1 was preferentially expressed (Figure 1C), This indicates a suppressive inflammatory response induced by prolonged treatment with ENZ through reciprocal inhibition of YAP/NFKB and ENZ>YAP-mediated suppression of apoptotic activation that typically results in cGAS/STING>pSTAT1, which is unmasked by J54 – Note that the success of ICB in combinatorial testing with different chemotherapeutics was generally not that great [33], making J54 even more remarkable.






Figure 1. Treatment of immunocompetent C57BL/6 mice inoculated with subcutaneous TRAMP-C2 xenografts in each flank. (A) The treatment effects on tumor growth revealed a significantly reduced tumor volume for the combination treatment in contrast to the ADT-mediated rapid tumor growth as quantified in (B) (n=5) (C) ADT-mediated tumor growth is characterized by increased expression of PD-L1, an ICI, which was significantly reduced by the J54 combination treatment. (D) Modulation of the TLK1 axis is accompanied by distinct immunomodulatory responses that characterize tumor growth parameters. Inhibition of the TLK1 axis fosters the expression of innate immune mediators. (E) A diagram illustrating the potential advantage of the combined treatment of ENZ and J54 compared to ENZ alone, aimed at enhancing antitumor immunity through selective modulation of STAT1/3.

TLKi and ICI Combination Increases PCa Tumor Immune Cell Infiltration

Prostate tumors are generally regarded as immunologically cold due to their low immune cell infiltration, often exemplified by the TRAMP-C2 models, which are well-characterized in terms of their immune properties. To evaluate the implications of differential expression of innate immune mediators on immune cell infiltration in these tumors, we inoculated 10⁶ TRAMP-C2 cells into each flank of C57BL/6 male mice. We treated them biweekly with ENZ, ATEZ, and/or J54 over four weeks. We performed immunohistochemical analysis to detect T-cells (CD3) and macrophages (F4-80) in tumor sections. Tumor sections from control and ENZ-alone groups showed sparse T-cell populations (Figure 2A). While the combination treatment of Atez and ENZ yielded a moderate increase in T-cell infiltration, treatment with J54 and ATEZ/ENZ resulted in a significant (p< 0.001) increase in T-cell populations, with relative infiltrations of 35% and 45%, respectively, compared to ENZ treatment alone (Figure 2A and B). Notably, the T-cell infiltration observed with the combination of ENZ and J54 was markedly more significant (p< 0.001) than other treatments, suggesting that J54 in combination with ENZ mediates a more robust mechanism for increased T-cell infiltration. The combination of all three drugs was only mildly effective in enhancing T-cell infiltration. Macrophage infiltration, assessed through F4-80 antibody detection, was significantly (p< 0.001) lower in the control, ENZ, and J54-treated groups (Figure 2C and D). In contrast, drug combinations increased the relative proportion of intratumoral macrophage densities (Figure 2C). Staining quantification of the infiltrated macrophages indicated a significant (p< 0.001) increase of approximately 65% infiltration in the J54 + ENZ treatment and 59% for the J54 and Atez treatment compared to 35% macrophage infiltration in the control group and those treated with ENZ (Figure 2D). Representative images (Figure 2 A and C) displayed dense T- cell and macrophage aggregates in the J54 and ENZ/Atez combinations compared to the sparse populations in the ENZ- treated groups, suggesting an active conversion of a cold tumor to a hot tumor that is densely populated

with immune cells. This presents great potential for an improved antitumor immune response; however, the functional activity of the T-cell and macrophage subtypes within the tumor needs further analysis.




Figure 2. CD3 T-cell infiltration of tumors from TRAMP-C2 xenografts. Inoculating 10% TRAMP-C2 cells into each flank of C57BL/6 mice treated with ENZ alone, ATEZ alone, J54 alone, or in combinations for 30 days led to increased T-cell infiltration in the combined treatments (ENZ+J54, ATEZ+J54) compared to the control and ENZ alone, indicating an immunologically active tumor. **(B)** Quantification of the CD3 T-cell infiltration reveals a significantly ($p<0.0001$) higher T-cell infiltration for the J54 and ENZ/Atez treatment groups compared to the untreated control or ENZ-treatment.





Figure 3. Macrophage infiltration of tumors from TRAMP-C2 xenografts. Inoculating 10⁶ TRAMP-C2 cells into each flank of C57BL/6 mice treated with ENZ alone, ATEZ alone, J54 alone, or in combinations for 30 days resulted in increased infiltration of macrophages to varying degrees in the respective treatments as detected using F4/80 antibody. **(B)** Quantification of the F4-80-cell infiltration reveals a significantly ($p<0.0001$) increased macrophage population for the J54 and ENZ/Atez treatment groups compared to the untreated control or ENZ-treatment.

TLKi and ICI combination modulates circulating cytokine expression for tumor regression.

To assess the levels of inflammatory response associated with tumor growth and immune response, we quantified the levels of pro-inflammatory (IL-6, IL-10, IL-4, and IL-1 β) and anti-inflammatory (IFN- γ , IL-2, and IL-12) cytokines in circulating blood samples collected at the end of the study. The circulating levels of anti-inflammatory cytokines (IFN- γ , IL-2, and IL-12), which were reduced in control, ENZ, and ENZ + Atez treatments, significantly increased ($p<0.001$) with the J54 and ENZ/Atez treatments (Figure 4). Conversely, the J54 and ENZ/Atez treatments significantly reduced the expression of the anti-inflammatory cytokines IL-4, IL10[34] compared to the control and ENZ groups (Figure 4). No other particular trend was observed for the other cytokines. This suggests a possible cytokine-mediated regulation of immune homeostasis that supports tumor suppression or regression. Specifically, these data demonstrate J54 and ENZ/Atez-mediated shift towards pro-inflammatory cytokine profiles and reduced anti-inflammatory pathways that inhibit tumor regrowth or recurrence.




Figure 4. Treatment-induced expression of cytokines. The J54 combination treatment increases the expression of pro-inflammatory cytokines (IFN- γ , IL-12, and IL-2), which are reduced by ADT. In contrast, the increased expression of pro-resolving cytokines, IL-10 and IL-4, which are immunosuppressive, induced by ADT, was significantly reduced by J54 combination treatment. Data represent mean $\pm$ SE.

Identification of qPCR-Based Immune Cell Phenotyping in the Blood of Tumor-Bearing Mice

Due to the scarce white cells blood component of the mice in the different treatment group for characterization by the standard FACS methods, we set out to address this issue via qRT-PCR of total RNA isolated from the blood cell pellets in order to assess particularly the mean levels of circulating T-cells and establish if there is an overt increase in tumor-attacking leukocytes. Although such a method was established before [35] we validated it in our study by comparing the results based on IHC of tumor slices matched by an analysis of CD3-expressing cells at the transcript level from total RNA isolated from a small amount (~5mg) of tumor tissue. As shown in Figure 5, the same treatment groups that displayed the highest infiltration of T-cells by IHC also displayed the highest presence of CD3-encoding mRNA. This method is similar to collective sc identification.




Figure 5. Determination of infiltrating CD3 cells in tumors via qRT-PCR.

Identification of qPCR-Based Immune Cell Phenotyping in the Blood of Tumor-Bearing Mice

Due to the scarce white cells component of the mice in the different treatment group for characterization by the standard FACS methods, we set out to address this issue via qRT-PCR of total RNA isolated from the blood cell pellets in order to assess particularly the mean levels of circulating T-cells and establish if there is an overt increase in tumor-attacking leukocytes. Although such a method was established before [35], we wanted to validate it for our study by comparing whether the results based on IHC of tumor slices could be matched by an analysis of CD3-expressing cells at the transcript level from total RNA isolated from a small amount (~5mg) of tumor tissue. As shown in Figure 5, the same treatment groups that displayed the highest infiltration of T-cells by IHC also displayed the highest presence of CD3-encoding mRNA, similar to a collective sc identification.

Identification of qPCR-Based Immune Cell Phenotyping in the Blood of Tumor-Bearing Mice

Mapping the immune infiltrate component in the TRAMPxNek1^{+/-} PCa model

We have previously reported preliminary observations that TRAMP mice haploinsufficient for Nek1, even at sexual maturity and beyond (24 w of age) usually do not progress beyond PIN and into invasive PRAD, but rarely, if castrated, develop NEPC more readily than wt-TRAMP (castrated or not) at 24 w [13]. We suggested with the inclusion of IHCs that these processes (or lack thereof) in the Nek^{+/-} mice seem to depend on pYAP1-Y407 and its now demonstrated stabilization[13,14]. Indeed, IHC for chromogranin in aged+castrated mice, only in this group, occasionally displays more than minimal, sporadic staining (SI-file1 and summarized in Table 1). We have also previously reported that YAP1 loss in the TRAMP lesions correlates with the development of NEPC features at this age [36].

Table 1. caption.

	Genotype							
	NEK1 ^{+/+} Non Cas		NEK1 ^{+/+} Castrated		NEK1 ^{-/-} Non cas		NEK1 ^{-/-} Castrated	
Markers	Nuclear	Cytoplasmic	Nuclear	Cytoplasmic	Nuclear	Cytoplasmic	Nuclear	Cytoplasmic
YAP1	negative	2-3 out of 3	2-3 out of 3	3 out of 3	negative	2 out of 3	negative	2 out of 3
pNek1	negative	2-3 out of 3	negative	3 out of 3	negative	2 out of 3	negative	2 out of 3
N-Cadherin	negative	negative vs 3	negative	negative	negative	1-2 out of 3	negative	negative
E-Cadherin	negative	1 out of 3	negative	3 out of 3	negative	2 out of 3	sporadic	2-3 out of 3
ChrA	negative	negative	negative	negative	negative	negative	sporadic	mild apical




Figure 6. Assessment of circulating leukocytes in tumor-bearing mice from different treatment groups revealed changes in CD3, CD4, CD8, and F4/80 mRNA, as determined by qRT-PCR. Western blot analysis demonstrated treatment-induced variations in markers for intratumoral immune cell subsets. (A) Combination treatments showed increased levels of CD3 mRNA compared to ADT and single treatments, indicating a potential rise in circulating T-cell markers. (B) Atezolizumab, combined with ENZ and J54 treatments, as well as the triple treatment combinations, induced CD8 gene expression, suggesting an enhanced presence or activation of CD8 T-cells. (C) The upregulation of CD4 gene expression implies an increased presence of circulating CD4+ T-cells following combination treatments. (D) qRT-PCR revealed elevated expression of F4/80 after treatment with the ENZ and J54 combination, reflecting enhanced signatures associated with circulating macrophages. (E) Combined treatments exhibited increased expression of the antitumoral macrophages (M1) marker (CD86) alongside a corresponding rise in CD8 markers, in contrast to the low expression seen in the control and ADT mice groups, where the tumor-associated macrophage (M2) marker (CD206) is more prominent. Data represent mean $\pm$ SD from n=3 replicates.

VISIUM spatial analysis of FFPE sections in the TRAMP/Nek1 haploinsufficient model: In order to study these features more accurately at the single-cell transcriptional level, we employed the use of VISIUM on a pair of randomly selected samples from the ‘rare’ PRAD that were identified via IHC in the castrated TRAMPxNek1^{+/-} sections, compared to the matched Nek1^{+/+} animals. Two key sets of data were of particular interest to us from these specimens: 1) the proportion of infiltrating immune cells; 2) the proportion of putative NEPC cells in those sections (Figure 7 and SI-file2). We also aimed to solidify the hypothesis that Nek1 is critical for PCa progression in TRAMP via upregulation of YAP, and more so after castration because of increased TLK1B expression [37], all

this by generating TRAMP/Nek1^{kat-2j} mice. We earlier reported that while intact TRAMP/Nek1^{+/+} mice develop PCa rather normally with much enlargement of the prostate at 18-20 weeks, if mice are castrated, the tumors usually fail to grow [13]. IHC of prostates from castrated TRAMP/Nek1^{+/+} was unable to reveal bona fide tumor areas (only hyperplasia/PIN), and pNek1 and YAP1 staining was strongly reduced while EMT markers were curtailed [13]. Nek1 is essential for YAP1 accumulation [9,14], CRPC progress [38–40], and immune evasion[18] but its expression is decreased during (often therapy-driven) NEPC transdifferentiation [36,41]. TRAMP mice haploinsufficient for Nek1 revealed a greatly reduced YAP1 expression and YAP and EMT genes signatures (SI-file 2-3). We suggested with the inclusion of IHCs that these processes (or lack thereof) in the Nek^{+/+} mice seem to depend on pYAP1-Y407 and its now demonstrated stabilization[13,14]. Very notable is significant proportion of B cells, dendritic, and macrophages in the TME of castrated TRAMPxNek1^{+/+} sections. The high importance of a considerable infiltration of B cells in the TME and in attacking the tumor cells has been often downplayed [42]. The difference in the volumes of these prostate adenocarcinomas from matching random sets of castrated animals is also quite noticeable as is number of proliferating PRAD cells based primarily on PCNA and Ki67 expression, with the TRAMP-wt exhibiting large tumors and the Nek1^{+/+} presenting much smaller ones. Additionally, the increased presence of NEPC cells and ‘fibroblasts tissue replacement’ in the Nek1 haploinsufficient mice is very noticeable, as they display reduced YAP1 expression.




Figure 7. Spatial rendering of main cells in castrated TRAMP-wt (top slices) and Nek1^{+/+}(bottom slices).

Discussion

Our study demonstrates that the combination of J54 and ENZ exerts the most potent anti-tumor effects, characterized by a significant reduction in tumor volume, enhanced immune cell infiltration, favorable shifts in the tumor immune microenvironment, and increased levels of anti-inflammatory cytokines. These findings provide compelling insights into the therapeutic benefits of this combination regimen and predict a complementary mechanism that appears to have improved immunomodulatory functions.

The observed suppression of tumor growth in the J54 and ENZ combination treatment groups, which outweighs that of either the drug alone or the control group, suggests a synergistic interaction between J54 and ENZ. This is particularly significant given that either drug alone worsens tumor

growth, while Atez was primarily cytostatic when used alone or combined with ENZ, perhaps due to the activation of compensatory resistance mechanisms that drive tumor growth in each case. J54 + Atez also proved to be effective against tumor volume, while the combination of the three drugs was cytostatic, an effect that could have resulted from a complicated drug-drug interaction. The significant tumor regression observed with J54 and ENZ/Atez may reflect complementary modes of action whereby J54 exerts a cytotoxic effect via increased apoptosis and aids the other drugs in priming the tumor immune microenvironment to facilitate sustained immune-mediated control of tumor growth. The variability in the effects of J54 + ENZ and J54 + Atez suggests that there is an additional mechanism beyond the modulation of PD-L1 expression that is mediated by the J54 + ENZ, which accounts for the improved effect.

The expression of TLK1B is regulated translationally via the mTOR>4EBP pathway, most commonly in response to survival 'emergency' situations. It is conceivable that ICB treatment, which unmasks the existence of the tumor and makes it accessible to immune attack, could be one such situation for the cancer cells. Conversely, the concomitant inhibition of TLK1/1B (a mediator of survival response) would be expected to elicit a high-level apoptotic response, resulting in a reduction of tumor mass and cells, and leading to the preferential loss of high turnover proteins like TLK1B. Direct evidence that tumors become immunologically hot is provided through IHC determination of infiltrating immune cells and the detection of specific cytokines present in the plasma.

Interestingly, a central finding of this study is the increased infiltration of immune effector cells – particularly T-cells and macrophages – into the tumor mass following combination treatment. The components of the tumor microenvironment, including a dense stroma, immunosuppressive myeloid-derived suppressor cells, and T regulatory cells (Tregs), contribute to the scarcity of intratumoral immune cells⁽⁶⁶⁾. Effective therapies often aim to enhance immune cell infiltration, thereby facilitating immune-mediated control of tumor growth. IHC revealed both elevated immune cell density and percentage infiltration of T-cells and macrophages with J54 and ENZ/Atez treatment, a hallmark of improved tumor immunogenicity. This can be interpreted as converting the originally cold tumor into a hot one, making it susceptible to immune cell-mediated control of tumor growth. This J54 combination therapy overcame immune exclusion or stromal barriers often associated with immunologically "cold" tumors. Macrophages present within the tumor microenvironment can be either proinflammatory, tumoricidal M1 macrophages or the immunosuppressive, tumor-promoting M2 subtypes. Beyond enhancing the quantity of T-cell infiltrates, our combination therapies also appear to target the M1/M2 reprogramming without significantly affecting the number of intratumoral macrophages. This likely transforms the tumor-associated macrophages into allies of the immune system, facilitating an immune-controlled attack on the tumor. The increased immune cell infiltration correlates with significant tumor regression, suggesting that these cells may exert cytotoxic mechanisms that prevent tumor growth.

Mechanistically, PD- L 1 reduction in the J54 and ENZ/Atez groups, compared to other groups, correlates with reduced flux through the TLK 1> Nek 1> YAP 1 axis and is characterized by increased expression of STAT 1 but not STAT 3. The balance of STAT 1 and STAT 3 involves shaping tumor immune responses toward immunosuppression or an antitumor response. The increased STAT 1 in the J54 and ENZ/Atez treatment groups, which correlates with tumor regression, suggests the initiation of signaling that enhances cytotoxic function and effector T-cell activity, likely resulting from both direct tumor cell priming and the reversal of immunosuppressive signals within the tumor environment. Hence, reducing the ICI molecule – PD- L 1 facilitates immune surveillance. In contrast, STAT 3, which is highly expressed in the control and monotherapy groups, correlates with increased PD-L1, likely activating immunosuppressive signals or creating a pro-tumorigenic environment that drives tumor growth. Interestingly, the combination treatment also led to elevated expression of anti-inflammatory cytokines such as IFN- γ , IL- 2, and IL- 12, which were predicted to rise by analogy to the VCaP model after observing the profound increase in pSTAT 1, without the concomitant increase in pro-inflammatory cytokines, especially IL- 10 and IL- 4, which are crucial for immunosuppression.

Furthermore, PD- L 1 expression is known to be regulated by $\text{INF}\gamma$ and IL- 2 through STAT 1 and STAT 3 signaling [66]. Over the past two decades, interleukin- 12 (IL- 12) has emerged as one of the most potent cytokines in mediating antitumor activity in various preclinical models [66]. In contrast, the fact that IL-10 doesn't appear to change with the various treatments of interest is actually more significant than it is often credited for, as it typically limits inflammation[66]. This observation suggests that J54 and ENZ/Atez promote the resolution of inflammation while enhancing antigen presentation. This also correlates limiting tumor-promoting inflammation with improved cytotoxic responses. Perhaps the reduction in IL- 10, which normally favors T- regulatory cells, accompanied by the increased IL- 12 and $\text{IFN-}\gamma$, may serve as a regulatory role that promotes immune-mediated control and sustains effective anti-tumor immunity.

The TC2/C57Bl6 was the simplest syngeneic mouse PCa syngeneic model available to us for rapid analysis, but we wanted to expand on its generality and utility with a more genetically tractable with the inclusion of our previously developed TRAMPxNek1^{+/-} GEMM. In this model, the normally increased TLK1B expression after castration or ARSI and typically leading to the activation of NEK1>YAP stabilization axis, is curtailed due to Nek1 haploinsufficiency, and indeed the expression of YAP was demonstrated to be strongly reduced (Table 1 and [6]). The consequence of this was not fully appreciated in that report, although we had observed the significant decrease in frequency of overt adenocarcinomas of their prostates (PRAD) and the better life expectancy of those mice (beyond 30 weeks of age – endpoint when we sacrificed all animals to investigate their prostates). As shown in Figure 7 for the few animals (~15%) in which PRAD was confirmed, the tumors volumes were noticeable smaller, and the subsequent FFPE VISUM sections of two randomly selected mice, vs control (also castrated) wt-TRAMP mice, displayed a vastly different map of the main cell types present in the lesions, with a much stronger presence of various immune cells infiltrates in the TME and much reduced representation of PRAD cells. It is difficult to escape the general conclusion that the TLK1B.NEK1.YAP axis is of critical importance for development and progression of PRAD after castration, although not to NEPC.

Conclusions

The combined effects of J54 and ENZ/Atez on tumor shrinkage, immune infiltration, and anti-inflammatory cytokine expression could be therapeutically beneficial for single-agent immunotherapies for PCa. Its dual action on tumor intrinsic signals and the tumor microenvironment is critical for overcoming immune resistance to achieve a robust response. In the context of immune cold tumors (most PCa), the ability of this combination therapy to enhance immune cell infiltration without inducing systemic cytokine toxicity may be highly beneficial for improving PCa patient survival.

Materials and Methods

J54 was purchased from Probechem (TLK1 inhibitor J54|TLK1 inhibitor|Probechem Biochemicals, China) while Enzalutamide (AR inhibitor) and Atezolizumab (PD-L1 inhibitor) were purchased from BOC Sciences, NY, USA, and Targetmol Chemicals, MA, respectively.

Animal Studies

All animals involved in this study received humane care following the guidelines of the American Veterinary Medical Association. The Institutional Animal Care and Use Committee of the LSU Health Sciences Center at Shreveport approved all testing protocols. Male C57BL/6 mice (Charles River, Skokie, IL, USA) were utilized to host TRAMP-C2 prostate cancer tumors, with 0.5×10^6 TRAMP-C2 cells grafted subcutaneously into the lower back flanks of the mice. Once the tumors reached approximately 100 mm³ in size, the tumor-bearing mice were randomized into eight treatment groups. The treatments included a vehicle control (PBS), an AR inhibitor ENZ (10 mg/ml), a PD-L1 inhibitor ATEZ (400 µg/100 µl), a TLK1-NEK1 inhibitor J54 (10 mg/kg), combinations of J54

with ENZ or ATEZ, and a triple drug combination. All treatments were administered orally and given bi-weekly. The dosing for J54 was determined based on our previous research. Tumor sizes were measured every other day using calipers. The inhibition treatment continued for 28 days, equivalent to roughly nine bi-weekly cycles. Mice were sacrificed at the experiment's conclusion using CO₂ asphyxiation, and the tumors were excised for tissue Western blots or immunohistochemistry (IHC). Blood samples were also collected for further analysis. Whole blood was centrifuged at 3000 rpm for 15 minutes at 4 °C, and the supernatant was stored at -80 degrees for future use. The packed cell pellet was utilized for RNA extraction using the Trizol-chloroform method.

Western Blot

Western blots were performed in three biological replicates utilizing tumors excised from various treatment groups, including the control (PBS). The frozen tumor tissues were disrupted using the Bioruptor® Plus sonication device (Diagenode), then homogenized and lysed in ice-cold RIPA lysis buffer system (Santa Cruz Biotechnology, Dallas, TX, USA). Samples were centrifuged at 13,000 rpm for 20 minutes at 4 °C. The supernatant was collected, transferred into fresh 1.5 mL microfuge tubes, flash-frozen, and stored at -80 °C until needed. Total protein concentration was assessed using a Pierce™ BCA protein assay kit (Thermo Scientific, Waltham, MA, USA), employing bovine serum albumin (BSA) as the standard control. The sample supernatant underwent denaturation with 1X Laemmli Buffer for 10 minutes at 95 °C and was subsequently separated using a 10% PROTEAN TGX protein gel (BioRad, Hercules, CA, USA). Proteins were transferred to the Immun-Blot PVDF membrane (BioRad) with a Criterion Blotter at 100 volts on ice. The membrane was blocked using 5% non-fat dry milk in 1X Tris-buffered saline with Tween-20 (TBST) for 1 hour at room temperature. Following this, the membrane was washed three times with 1X TBST and incubated overnight at 4 °C with gentle rocking in a solution containing mouse anti-PD-L1 antibody (Thermo Scientific; Cat. No. 14-5983-82), anti-pSTING (Cell Signaling Technology; Cat. No. 19781S), anti-pSTAT3 (Cell Signaling Technology; Cat. No. 9145S), anti-Pstat1 (Cell Signaling Technology; Cat. No. 9167S), along with anti-pYAP1-Y407, anti-pNek1-T141, and anti-TLK1 (Thermo Scientific) antibodies diluted in 5% BSA in 1X TBST. After washing, the membranes were incubated for 1 hour at room temperature with either horse anti-mouse or anti-rabbit antibodies (Cell Signaling Technology) conjugated with horseradish peroxidase in 5% BSA in 1X TBST. Once incubation was complete, the membrane was washed, and bands were visualized using a Pierce™ ECL Western Blotting Substrate (Thermo Scientific) Cat. No. 32106) on the ChemiDoc MP Imaging System.

ELISA

This was done using the mouse immune response ELISA Strip (Signosis Inc., CA, USA, Catalog No: EA-1171). Briefly, 100 µL of serum per well was incubated for 2 hours at room temperature with gentle shaking. Each well was aspirated and washed thrice with 200 µL of wash buffer. 100 µL of biotin-labeled antibody was added to each well and incubated for 1 hour with gentle shaking. The washing with wash buffer was repeated three times. 100 µL of streptavidin-HRP was added to each well and incubated for 45 minutes at room temperature. The wash step was repeated afterward. 100 µL of substrate was added to each well and incubated for 30 minutes, after which 50 µL of stop solution was added. The optical density was determined at 450 nm using a microplate reader. The concentrations were then calculated using the appropriate conversions.

Immunohistochemistry

Tissues were sectioned and mounted on slides, dried, deparaffinized, and rehydrated using xylene and a graded ethanol series (100% - 70%, followed by water). Antigen retrieval was performed, followed by a peroxidase block. Slides were incubated with blocking buffer for 30 minutes. Overnight incubation with primary antibodies (F4-80 OR CD3) was conducted at 4 degrees. The slides were

washed three times with PBS for 5 minutes each and incubated with an HRP-conjugated secondary antibody for 30 minutes. 3,3'-diaminobenzidine (DAB) was added and incubated for about 8 minutes to develop color. Counterstaining with hematoxylin was performed, followed by dehydration using graded ethanol to xylene. The slides were mounted with a resin-based medium. Images were captured under the microscope. Immune cell quantification was conducted using QuPath Open Software.

RT-PCR

RT-PCR was carried out using SYBR Green Master Mix in a 20 μ L reaction. Gene-specific primers were designed and synthesized by IDT. Below is a list of the primer sequences for the respective genes used for RT-PCR studies in 5'–3': F—forward (sense primer), R—reverse (antisense primer). Relative gene expression levels were calculated using the ddCt method, with the housekeeping gene (GAPDH) used as an internal control. Each sample was analyzed in triplicate.

GENES	PRIMER SEQUENCES
CD3	F: GCGTCTGGTGCCTTCTTCAG R: CAATGTTCTCGGCATCGTCCT
CD4	F: TTCTGGCAACCTGACTCTGAC R: ACCCCTCTGGATAAAACCTGGA
CD8	F: ACTTCAGTTCTGTCGTGCCA R: GCAAACACGCTTTCGGCTC
F4/80	F: CCTCTGTGCCTTTGGCTATGG R: TGAAGGTCAGCAACCTCGTG

Spatial Transcriptomics

Spatial transcriptomics data were generated from four mouse prostate tissue sections using the 10x Genomics Visium platform. For each sample, raw data were processed using Space Ranger. The resulting outs directory, which includes the high-resolution tissue image, was used for downstream analysis in the R environment with Seurat (<https://github.com/satijalab/seurat>). Spots with low spatial UMI counts (`nCount_Spatial` <= 1000) were filtered out. The data were then normalized and variance stabilized using SCTransform with the "Spatial" assay. Principal component analysis (PCA) was performed on the SCTransformed data (`RunPCA`), and the top 50 principal components were used for downstream analyses. Neighborhood graph construction (`FindNeighbors`) and Louvain clustering (`FindClusters` with `resolution = 2`) were completed, followed by Uniform Manifold Approximation and Projection (UMAP) for visualization (`RunUMAP`).

A previously annotated single-cell RNA sequencing (scRNA-seq) dataset (MoPSA PMID: 39095562) was utilized as a reference for cell type deconvolution. The reference dataset was then downsampled to 1500 cells (`subset(x = data, downsample = 1500)`) and normalized using SCTransform. To infer cell type composition within each Visium spot, label transfer was performed using the prepared scRNA-seq reference. Anchors between the reference and each Visium query dataset were identified using `FindTransferAnchors` with the "SCT" normalization method. Cell type probabilities were subsequently transferred to the Visium spots using `TransferData`. From the prediction scores for each spot, the cell type with the highest probability was assigned as `Dominant_type1`, while the cell type with the second highest probability was designated as `Dominant_type2`. These dominant cell type annotations were included in the metadata of each Visium Seurat object. The spatial distribution of clusters and cell types was visualized using `SpatialDimPlot`. Quality control metrics (`nCount_Spatial`, `nFeature_Spatial`) and gene expression were visualized using `SpatialFeaturePlot` and `VlnPlot`. Gene set module scores were calculated to assess pathway activity. Epithelial-Mesenchymal Transition (EMT) scores were computed using the `AddModuleScore_UCell` function with a gene set derived from "HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION.v2023.1.Mm.grp.csv". Similarly,

YAP activity scores were determined using AddModuleScore_UCell with a gene set from "CORDENONSI_YAP_CONSERVED_SIGNATURE.v2023.2.Hs.grp.csv"; human gene symbols in this set were converted to their mouse orthologs using nichenetr::convert_human_to_mouse_symbols prior to scoring. The resulting module scores (e.g., "EMT_UCell", "YAP_UCell") were visually represented spatially using SpatialFeaturePlot and across clusters/dominant types using VlnPlot. ImageJ quantification of area was used to quantify specific cell area.

Statistical Analysis

All statistical analyses were conducted using GraphPad Prism 10.0. Data quantifications are expressed as mean ± standard deviation (SD). Statistical significance was calculated by a one-way ANOVA followed by Tukey’s post hoc analysis when comparing more than two groups. All p-values < 0.05 and < 0.001 were deemed statistically significant.

Author Contributions: Conceptualization by A.D.B. and D.M., manuscript writing: A.D.B., D.O., O.F, and X.Y.; methodology: A.D.B, O.F., and D.O.; experiment analysis and interpretation: A.D.B., D.O., O.F, and X.Y.; IHC analysis: A.D.B., D.O., O.F, and X.Y. All authors have read and agreed to the published version of the manuscript.

Supplementary Materials: The following supporting information can be downloaded at the website of this paper posted on Preprints.org.

Funding: This work was supported by a DoD-PCRP grant W81XWH-17-1-0417 and grants from Feist-Weiller Cancer Center (FWCC) of LSU Health Shreveport to ADB.

Institutional Review Board Statement: The animal study protocol was approved by the Institutional ACUC – protocols P-20-24 TARGETING THE TLK1/NEK1 AXIS IN PROSTATE CANCE, and S-24-004 COMBINING ANTIANDROGEN+J54 WITH AVELUMAB FOR PCA TREATMENT. Approved 5-29-2024, for studies involving animals.

Data Availability Statement: Description of all data and materials can be found in the referenced article. No additional data have been withheld from the public.

Acknowledgments: We would like to thank the INLET facility of LSU Health Shreveport, especially Camille Canon, for expert assistance preparation of the IVIS libraries. We also would like to thank the Research Core Facility Genomics Core and animal facility of LSU Health Shreveport for help with the qPCR analysis and animal work. A particular thanks to Siyuan Cheng for developing algorithms in R, expert Bioinformatics analysis, interpretation and visualization of theVISIUM datasets.

Conflicts of Interest: Authors declare no conflicts of interest.

References

1. Chen Y, Clegg NJ, Scher HI: **Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target.** *Lancet Oncol* 2009, **10**(10):981-991.
2. Chism DD, De Silva D, Whang YE: **Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer.** *Expert Rev Anticancer Ther* 2014, **14**(11):1369-1378.
3. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B *et al*: **Integrative genomic profiling of human prostate cancer.** *Cancer Cell* 2010, **18**(1):11-22.
4. Salem O, Hansen CG: **The Hippo Pathway in Prostate Cancer.** *Cells* 2019, **8**(4).
5. Singh V, Jaiswal PK, Ghosh I, Koul HK, Yu X, De Benedetti A: **Targeting the TLK1/NEK1 DDR axis with Thioridazine suppresses outgrowth of androgen independent prostate tumors.** *International journal of cancer* 2019, **145**(4):1055-1067.
6. Singh V, Jaiswal PK, Ghosh I, Koul HK, Yu X, De Benedetti A: **The TLK1-Nek1 axis promotes prostate cancer progression.** *Cancer Letters* 2019, **453**:131-141.

7. Liu S, Ho CK, Ouyang J, Zou L: **Nek1 kinase associates with ATR-ATRIP and primes ATR for efficient DNA damage signaling.** *Proc Natl Acad Sci U S A* 2013, **110**(6):2175-2180.
8. Wengner AM, Scholz A, Haendler B: **Targeting DNA Damage Response in Prostate and Breast Cancer.** *Int J Mol Sci* 2020, **21**(21).
9. Khalil MI, Ghosh I, Singh V, Chen J, Zhu H, De Benedetti A: **NEK1 Phosphorylation of YAP Promotes Its Stabilization and Transcriptional Output.** *Cancers* 2020, **12**(12):3666.
10. Zhang L, Yang S, Chen X, Stauffer S, Yu F, Lele SM, Fu K, Datta K, Palermo N, Chen Y *et al*: **The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells.** *Mol Cell Biol* 2015, **35**(8):1350-1362.
11. Nguyen LT, Tretiakova MS, Silvis MR, Lucas J, Klezovitch O, Coleman I, Bolouri H, Kutayavin VI, Morrissey C, True LD *et al*: **ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors.** *Cancer Cell* 2015, **27**(6):797-808.
12. Singh V, Bhoir S, Chikhale RV, Hussain J, Dwyer D, Bryce RA, Kirubakaran S, De Benedetti A: **Generation of Phenothiazine with Potent Anti-TLK1 Activity for Prostate Cancer Therapy.** *iScience* 2020, **23**(9):101474.
13. Ghosh I, Khalil MI, Mirza R, King J, Olatunde D, De Benedetti A: **NEK1-Mediated Phosphorylation of YAP1 Is Key to Prostate Cancer Progression.** *Biomedicines* 2023, **11**(3):734.
14. Olatunde D, De Benedetti A: **TLK1>Nek1 Axis Promotes Nuclear Retention and Activation of YAP with Implications for Castration-Resistant Prostate Cancer.** *Cancers* 2024, **16**(16):2918.
15. Janse van Rensburg HJ, Azad T, Ling M, Hao Y, Snetsinger B, Khanal P, Minassian LM, Graham CH, Rauh MJ, Yang X: **The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.** *Cancer Res* 2018, **78**(6):1457-1470.
16. Murakami S, Shahbazian D, Surana R, Zhang W, Chen H, Graham GT, White SM, Weiner LM, Yi C: **Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma.** *Oncogene* 2017, **36**(9):1232-1244.
17. Collak FK, Demir U, Sagir F: **YAP1 Is Involved in Tumorigenic Properties of Prostate Cancer Cells.** *Pathol Oncol Res* 2020, **26**(2):867-876.
18. Hu X, Zhang Y, Yu H, Zhao Y, Sun X, Li Q, Wang Y: **The role of YAP1 in survival prediction, immune modulation, and drug response: A pan-cancer perspective.** *Frontiers in Immunology* 2022, **13**.
19. Kim MH, Kim CG, Kim SK, Shin SJ, Choe EA, Park SH, Shin EC, Kim J: **YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma.** *Cancer Immunol Res* 2018, **6**(3):255-266.
20. Miao JB, Hsu PC, Yang YL, Xu ZD, Dai YY, Wang YC, Chan G, Huang Z, Hu B, Li H *et al*: **YAP regulates PD-L1 expression in human NSCLC cells.** *Oncotarget* 2017, **8**(70):114576-114587.
21. Yang HT, Chen HJ, Luo SM, Li LN, Zhou SJ, Shen RF, Lin H, Xie XH: **The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC.** *Oncotarget* 2017, **8**(14):23517-23528.
22. Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, Wu W, Han L, Wang S: **The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers.** *Front Immunol* 2022, **13**:964442.
23. Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X *et al*: **Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.** *Cell Rep* 2017, **19**(6):1189-1201.
24. Wang M, Ran X, Leung W, Kawale A, Saxena S, Ouyang J, Patel PS, Dong Y, Yin T, Shu J *et al*: **ATR inhibition induces synthetic lethality in mismatch repair-deficient cells and augments immunotherapy.** *Genes Dev* 2023, **37**(19-20):929-943.
25. Zheng W, Liu A, Xia N, Chen N, Meurens F, Zhu J: **How the Innate Immune DNA Sensing cGAS-STING Pathway Is Involved in Apoptosis.** *Int J Mol Sci* 2023, **24**(3).
26. Singh V, Khalil MI, De Benedetti A: **The TLK1/Nek1 axis contributes to mitochondrial integrity and apoptosis prevention via phosphorylation of VDAC1.** *Cell Cycle* 2020, **19**(3):363-375.
27. Deng Y, Lu J, Li W, Wu A, Zhang X, Tong W, Ho KK, Qin L, Song H, Mak KK: **Reciprocal inhibition of YAP/TAZ and NF- κ B regulates osteoarthritic cartilage degradation.** *Nature Communications* 2018, **9**(1):4564.

28. Jayaprakash P, Ai M, Liu A, Budhani P, Bartkowiak T, Sheng J, Ager C, Nicholas C, Jaiswal AR, Sun Y *et al*: **Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy.** *J Clin Invest* 2018, **128**(11):5137-5149.
29. Wang I, Song L, Wang BY, Rezazadeh Kalebasty A, Uchio E, Zi X: **Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy.** *Am J Clin Exp Urol* 2022, **10**(4):210-233.
30. Stultz J, Fong L: **How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer.** *Prostate Cancer and Prostatic Diseases* 2021, **24**(3):697-717.
31. Ding P, Ma Z, Fan Y, Feng Y, Shao C, Pan M, Zhang Y, Huang D, Han J, Hu Y *et al*: **Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy.** *Genes Dis* 2023, **10**(3):848-863.
32. Cerasuolo M, Maccarinelli F, Coltrini D, Mahmoud AM, Marolda V, Ghedini GC, Rezzola S, Giacomini A, Triggiani L, Kostrzewa M *et al*: **Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate Cancer.** *Cancer Res* 2020, **80**(7):1564-1577.
33. Patel SA, Minn AJ: **Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies.** *Immunity* 2018, **48**(3):417-433.
34. Nikovics K, Favier AL, Rocher M, Mayinga C, Gomez J, Dufour-Gaume F, Riccobono D: **In Situ Identification of Both IL-4 and IL-10 Cytokine-Receptor Interactions during Tissue Regeneration.** *Cells* 2023, **12**(11).
35. Huang J, Demmler R, Mohamed Abdou M, Thoma O-M, Weigmann B, Waldner MJ, Stürzl M, Naschberger E: **Rapid qPCR-based quantitative immune cell phenotyping in mouse tissues.** *Journal of Investigative Medicine* 2024, **72**(1):47-56.
36. Cheng S, Prieto-Dominguez N, Yang S, Connelly ZM, StPierre S, Rushing B, Watkins A, Shi L, Lakey M, Baiamonte LB *et al*: **The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer.** *Prostate Cancer Prostatic Dis* 2020, **23**(4):661-669.
37. Singh V, Jaiswal PK, Ghosh I, Koul HK, Yu X, De Benedetti A: **The TLK1-Nek1 axis promotes prostate cancer progression.** *Cancer Lett* 2019, **453**:131-141. DOI 110.1016/j.canlet.2019.1003.1041. Epub 2019 Mar 1027.
38. Lee H-C, Ou C-H, Huang Y-C, Hou P-C, Creighton CJ, Lin Y-S, Hu C-Y, Lin S-C: **YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer.** *Oncogene* 2021, **40**(13):2407-2421.
39. Cinar B, Al-Mathkour MM, Khan SA, Moreno CS: **Androgen attenuates the inactivating phospho-Ser-127 modification of yes-associated protein 1 (YAP1) and promotes YAP1 nuclear abundance and activity.** *J Biol Chem* 2020, **295**(25):8550-8559.
40. Kuser-Abali G, Alptekin A, Lewis M, Garraway IP, Cinar B: **YAP1 and AR interactions contribute to the switch from androgen-dependent to castration-resistant growth in prostate cancer.** *Nature Communications* 2015, **6**(1):8126.
41. Ito T, Matsubara D, Tanaka I, Makiya K, Tanei ZI, Kumagai Y, Shiu SJ, Nakaoka HJ, Ishikawa S, Isagawa T *et al*: **Loss of YAP1 defines neuroendocrine differentiation of lung tumors.** *Cancer Sci* 2016, **107**(10):1527-1538.
42. Largeot A, Pagano G, Gonder S, Moussay E, Paggetti J: **The B-side of Cancer Immunity: The Underrated Tune.** *Cells* 2019, **8**(5).

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.